Detalhe da pesquisa
1.
Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects.
Antimicrob Agents Chemother
; 54(8): 3170-8, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20498326
2.
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.
Clin Cancer Res
; 19(5): 1232-43, 2013 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23434733